Cibus (CBUS) Other Non-Current Assets (2016 - 2026)
Cibus (CBUS) posted Other Non-Current Assets of $926000.0 for Q4 2025, down 7.95% sequentially from $1.0 million in Q3 2025, and down 33.19% YoY from $1.4 million in Q4 2024.
Cibus (CBUS) Other Non-Current Assets (2016 - 2026) Analysis & Trends
Cibus has reported Other Non-Current Assets for 10 years, with the latest figure at $926000.0 in Q4 2025.
- Quarterly Other Non-Current Assets fell 33.19% year-over-year to $926000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $926000.0 (down 33.19% YoY) and the FY2025 annual result came in at $926000.0, down 33.19% from the prior year.
- Other Non-Current Assets declined to $926000.0 in Q4 2025 per CBUS's latest filing, from $1.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.5 million in Q2 2024 and troughed at $53000.0 in Q2 2022.
- A 5-year average of $874277.8 and a median of $1.0 million in 2025 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets tumbled 91.14% in 2022, then soared 2235.85% in 2023.
- Over 5 years, Other Non-Current Assets stood at $99000.0 in 2021, then tumbled by 46.46% to $53000.0 in 2022, then jumped by 2583.02% to $1.4 million in 2023, then slipped by 2.53% to $1.4 million in 2024, then tumbled by 33.19% to $926000.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $926000.0, $1.0 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | 771,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 771,000.00 |
| Dec 31, 2025 | 926,000.00 |
| Sep 30, 2025 | 1.01 Mn |
| Jun 30, 2025 | 1.07 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 1.39 Mn |
| Sep 30, 2024 | 1.46 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.42 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | 105,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 499,000.00 |
| Dec 31, 2021 | 99,000.00 |
| Sep 30, 2021 | 195,000.00 |
| Jun 30, 2021 | 598,000.00 |
| Mar 31, 2021 | 225,000.00 |
| Dec 31, 2020 | 280,000.00 |